News

A kidney relief  drug worth €673m
Enlarge image

BusinessSwedenUK

A kidney relief drug worth €673m

10.10.2012 - British-Swedish Astra Zeneca pays Californian start-up Ardelyx up to €673m to get hold on exclusive rights for their NHE3 inhibitor programme.

After a setback this summer with an anti-obesity drug, Astra Zeneca is trying to pick up pace by getting hold on a new class of drugs. The small molecules developed by Ardelyx from Fremont (USA) target a sodium transporter on the surface of the intestinal epithelia. Astra Zeneca sees promising options for the treatment of diseases ranging from cardiovascular defects to diabetes or chronic kidney problems. On 8 October, the two companies announced a worldwide exclusive licensing agreement for Ardelyx’s NHE3 inhibitor programme worth up to €673m. The lead compound – Phase 2-ready RDX5791 – showed activity against constipation-predominant irritable bowel syndrome (IBS-C) and is also clinically tested in end-stage renal disease (ESRD) and chronic kidney disease (CKD). Under the terms of the agreement, Astra Zeneca will pay €27m up-front. Development milestones could rinse another €184m into Ardelyx’ pockets. With launch and commercialisation milestones and tiered double-digit royalties, the whole deal could yield up to €673m. Ardelyx will fund Phase II trials and Astra Zeneca further clinical development.

Aside from RDX5791, several other compounds all targeting the main transporter of sodium in the intestines, NHE3, are also subject to the deal. The effect of RDX5791 can be compared with living on a low-salt diet. Preventing the uptake of sodium ions into the body unburdens failing kidneys to eliminate excess sodium. Blocked sodium will be excreted with the faeces instead. A positive systemic effect is that no sodium will accumulate in intravascular and interstitial tissues, so hypertension and oedema formation could be effectively averted. Beyond NHE3 inhibitors, Ardelyx has three separate non-systemic preclinical compounds that are all not covered by the Astra Zeneca deal. Although targeting different molecules in the gut, they share a common property in that they are not absorbed by the gastrointestinal epithelia and are passed through the gastrointestinal tract without being altered.

© eurobiotechnews.eu/ml

http://www.european-biotechnology-news.com/news/news/2012-04/a-kidney-relief-drug-worth-eur673m.html

ResearchEUUK

27.07.2016 In view of the Brexit, research academies across Britain are calling for a “bold commitment” from the government. The Royal Society President urges the UK government to underwrite the research of British scientists applying for EU funding.

FinancingBelgium

20.07.2016 Belgian molecular diagnostics company Biocartis Group NV has raised €55m and will use the funds mainly to expand manufacturing capacities for its PCR-based molecular diagnostics system Idylla.

Stock marketsFranceEU

19.07.2016 It is Europe’s first gene therapy company to float on Euronext: Gensight raised €40m in its IPO. And it is not the only French company that has taken the leap in an uncertain market climate – Alzheimer’s expert Pharnext also went public.

ResearchUK

18.07.2016 When NASA blasted off to the International Space Station on Monday morning, it had UK tech on board. A miniature DNA sequencer from Oxford Nanopore will be used to keep an eye on the ISS atmosphere – and may even analyse alien DNA one day.

M&AUKSwitzerland

13.07.2016 Cell Medica has acquired Swiss antibody specialist Delenex Therapeutics. The deal nets the British cellular therapeutics developer Delenex’ proprietory antibody fragment platform Pentrabody.

R&DAustriaFrance

12.07.2016 Vienna-based vaccine specialist Themis Bioscience GmbH has secured broad access to a promising virus vaccine vector tech by extending its license agreement with French Institut Pasteur. Its goal: to develop a Zika vaccine.

M&AFranceEU

07.07.2016 Californian biopharma Medivation has agreed to confidential negotiations with its suitors, in particular the French pharmaceutical company Sanofi, which aggressively has buffeted the cancer therapy specialist for months.

Prenatal DiagnosticsEUUK

06.07.2016 The European Commission started an investigation into Illumina’s and Sequenom’s 2014 patent agreement, UK-competitor Premaitha Health said. The two US companies had agreed to pool their Noninvasive Prenatal Testing IP.

GenericsSpainGermanyEU

04.07.2016 Cinfa Biotech is shuffling for position on the lucrative biosimilar market. The Spanish-German company has published positive results in a study for a pegfilgrastim copycat with 172 healthy volunteers in Germany.

Drug discoveryUKSwitzerland

30.06.2016 UK’s Heptares Therapeutics and Paul Scherrer Institute spinoff leadXpro will collaborate to find new approaches for the determination of high-res X-ray structures of G protein-coupled receptors to find new drugs.

Quick news provided by GlobeNewswire

View more stock news

Events

All Events

Partner-Events

Current issue

All issues

Product of the week

Products

Stock list

All quotes

TOP

  • NEWRON (CH)18.50 CHF9.14%
  • GENMAB (DK)1210.00 DKK5.68%
  • VALNEVA (F)2.42 EUR5.68%

FLOP

  • KAROLINSKA (S)7.30 SEK-3.95%
  • BIOTIE THERAPEUTICS (FI)0.27 EUR-3.57%
  • SAREUM HOLDINGS (UK)0.60 GBP-3.23%

TOP

  • PROTHENA PLC (IE)51.61 USD42.6%
  • PHARMING (NL)0.25 EUR31.6%
  • ACTIVE BIOTECH (S)11.95 SEK29.2%

FLOP

  • MOLOGEN (D)1.80 EUR-37.9%
  • SANTHERA (CH)56.40 CHF-20.6%
  • EVOCUTIS (UK)0.04 GBP-20.0%

TOP

  • KARO BIO (S)31.10 SEK1906.5%
  • NICOX (F)11.17 EUR481.8%
  • SAREUM HOLDINGS (UK)0.60 GBP172.7%

FLOP

  • BB BIOTECH (D)44.69 EUR-84.5%
  • NEUROVIVE PHARMACEUTICAL AB (S)4.87 SEK-77.6%
  • EVOCUTIS (UK)0.04 GBP-76.5%

No liability assumed, Date: 27.07.2016